Infinity stops cancer trial as drug fails to show Fri Jan 27, 2012 7:55am EST (Reuters) - Infinity Pharmaceuticals said it stopped a mid-stage trial of its experimental pancreatic cancer drug following an interim analysis that showed it would not meet its main goal. Data from the preliminary analysis showed that patients receiving placebo along with an anti-cancer chemotherapy drug lived longer than patients who received Infinity's drug saridegib plus the chemotherapy. Infinity is also testing saridegib in mid-stage trials as a single agent therapy in myelofibrosis -- a rare bone marrow disorder -- and a life-threatening cancer of the cartilage. The company expects to report data from the myelofibrosis mid-stage trial in the second half of 2012. Shares of the company closed at $9.95 on Thursday on the Nasdaq. Reporting by Anand Basu in Bangalore; Editing by Sriraj Kalluvila